Geron (GERN) Current Deferred Revenue (2010 - 2015)

Geron (GERN) posted Current Deferred Revenue of $35.0 million for Q2 2015, little changed sequentially from $35.0 million in Q1 2015.

Geron (GERN) Current Deferred Revenue (2010 - 2015) Analysis & Trends

Geron has reported Current Deferred Revenue for 3 years, with the latest figure at $35.0 million in Q2 2015.

Quarterly Current Deferred Revenue changed N/A year-over-year to $35.0 million in Q2 2015, while the trailing twelve-month figure through Jun 2015 was $35.0 million (changed N/A YoY) and the FY2014 annual result came in at $35.0 million, changed N/A from the prior year.
Current Deferred Revenue was little changed at $35.0 million in Q2 2015 per GERN's latest filing, from $35.0 million in the prior quarter.
Over five years, Current Deferred Revenue peaked at $35.0 million in Q4 2014 and troughed at $35.0 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Geron	1.02 Mn	-299.83 Mn	-

Download Data